Related Experiment Video
Updated: Jun 2, 2026

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
Published on: December 17, 2021
Emerging therapeutic targets in non-infectious uveitis and scleritis
Usanee Tungsattayathitthan1,2, Debra A Goldstein1, Timothy M Janetos1
1Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
None:
Non-infectious uveitis and scleritis are significant causes of visual impairment, and currently available targeted and effective therapeutic options remain limited. Multiple immunologic pathways are currently under investigation and targeted therapeutics have the potential to change the treatment landscape and improve visual outcomes. This review synthesizes potential upcoming local and systemic treatments for non-infectious uveitis and scleritis with a focus on therapeutics with human data, noting those with the most promising evidence, and areas of gaps in research.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
